Dnca Finance Has $8.49 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Dnca Finance reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,950 shares of the medical research company’s stock after selling 2,000 shares during the quarter. Dnca Finance’s holdings in Thermo Fisher Scientific were worth $8,494,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Chicago Partners Investment Group LLC raised its stake in shares of Thermo Fisher Scientific by 15.9% during the 1st quarter. Chicago Partners Investment Group LLC now owns 979 shares of the medical research company’s stock worth $487,000 after purchasing an additional 134 shares in the last quarter. LaSalle St. Investment Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 54.2% in the first quarter. LaSalle St. Investment Advisors LLC now owns 967 shares of the medical research company’s stock valued at $481,000 after buying an additional 340 shares in the last quarter. Finally, Savvy Advisors Inc. increased its holdings in Thermo Fisher Scientific by 20.8% during the first quarter. Savvy Advisors Inc. now owns 1,864 shares of the medical research company’s stock worth $928,000 after buying an additional 321 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Barclays lifted their price objective on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Hsbc Global Res raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, October 8th. Wells Fargo & Company increased their price target on Thermo Fisher Scientific from $565.00 to $635.00 and gave the company an “overweight” rating in a research note on Thursday, October 23rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $602.35.

Thermo Fisher Scientific Stock Performance

TMO opened at $572.49 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company has a market capitalization of $215.09 billion, a PE ratio of 33.07, a price-to-earnings-growth ratio of 4.19 and a beta of 0.90. The business has a fifty day simple moving average of $559.70 and a 200 day simple moving average of $485.50. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the previous year, the business posted $5.28 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its board has approved a stock repurchase plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 1,058 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total transaction of $622,379.08. Following the sale, the vice president directly owned 13,087 shares of the company’s stock, valued at approximately $7,698,558.62. This represents a 7.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Frederick M. Lowery sold 6,912 shares of the business’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total value of $4,022,369.28. Following the completion of the transaction, the executive vice president directly owned 14,367 shares of the company’s stock, valued at approximately $8,360,731.98. This trade represents a 32.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 149,271 shares of company stock valued at $86,507,282 in the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.